Comments
Lupin has launched Mycophenolate Mofetil Capsules USP, 250 mg in the US. Lupin’s alliance partner Concord Biotech had received approval from the USFDA earlier.
These capsules are an anti-metabolite immunosuppressant indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants and should be used in combination with other immunosuppressants. Mycophenolate Mofetil Capsules had annual sales of about $53 million in the US.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.